Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept.
Dilan YildizAkın ÇakırBurak ErdenSelim BolukbasiSerkan ErdenözMustafa Nuri ElciogluPublished in: Therapeutic advances in ophthalmology (2021)
Relaxed intravitreal aflibercept regimen has comparable efficiency and safety outcomes at 12 months with intensive intravitreal aflibercept regimen with fewer injections in the management of neovascular age-related macular degeneration.